Bullous pemphigoid during ustekinumab therapy

Bullous pemphigoid during ustekinumab therapy

BP: Bullous pemphigoid TNF-a: tumor necrosis factor-alfa INTRODUCTION Ustekinumab, a monoclonal antibody that blocks interleukin-12 and interleukin-23, is a biological therapy used to treat moderate-to-severe psoriasis. Bullous pemphigoid (BP) induced by antietumor necrosis factor-alfa (TNF-a) agents has been described in the literature. No cases have been reported with ustekinumab. We report a...

Development of bullous pemphigoid during nivolumab therapy

Bregs: B regulatory cells BP: bullous pemphigoid CTLA-4: cytotoxic T-lymphocyteeassociated protein 4 IRAE: immune-related adverse events PD-1: programmed cell death protein 1 PD-L1: programmed death ligand

A new approach on bullous pemphigoid therapy.

Bullous pemphigoid (BP) is the most common subepidermal autoimmune blistering skin disease seen in the elderly. The prognosis of BP is poor, since the 1-year mortality rate has been reported to range from 25% to 40% in recent studies [1]. Corticosteroids have been so far the mainstay of therapy [2]. Antibiotics and immunosuppressants, such as cyclophosphamide and azathioprine, have also been us...

Bullous pemphigoid

Bullous pemphigoid

Disease summary: Bullous Pemphigoid is an acquired, chronic, blistering autoimmune subepidermal bullous disease in which autoantibodies are directed against component of basement membrane zone of the skin [1]. It is characterized by formation of cutaneous bullae on the skin and mucous membrane. The pathogenesis involves migration of inflammatory cells into subepithilial tissues due to activatio...